MX9304152A - Inhibidores de enzimas. - Google Patents

Inhibidores de enzimas.

Info

Publication number
MX9304152A
MX9304152A MX9304152A MX9304152A MX9304152A MX 9304152 A MX9304152 A MX 9304152A MX 9304152 A MX9304152 A MX 9304152A MX 9304152 A MX9304152 A MX 9304152A MX 9304152 A MX9304152 A MX 9304152A
Authority
MX
Mexico
Prior art keywords
enzyme inhibitors
compounds
uracils
administration
side effects
Prior art date
Application number
MX9304152A
Other languages
English (en)
Inventor
James Leroy Kelley
David Patrick Baccanari Sr
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MX9304152A publication Critical patent/MX9304152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a ciertos inhibidores de enzimas (uracilos), los cuales son especialmente útiles para su coadministración con otros compuestos terapéuticos, tales como compuestos antivirales, con el objeto de proporcionar un efecto terapéutico mejorado, incluyendo reducción en los efectos secundarios tóxicos.
MX9304152A 1992-07-10 1993-07-09 Inhibidores de enzimas. MX9304152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929214720A GB9214720D0 (en) 1992-07-10 1992-07-10 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
MX9304152A true MX9304152A (es) 1994-04-29

Family

ID=10718537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304152A MX9304152A (es) 1992-07-10 1993-07-09 Inhibidores de enzimas.

Country Status (9)

Country Link
EP (1) EP0649413A1 (es)
JP (1) JPH07508983A (es)
AU (1) AU4511693A (es)
CA (1) CA2139836A1 (es)
GB (1) GB9214720D0 (es)
IL (1) IL106290A0 (es)
MX (1) MX9304152A (es)
WO (1) WO1994001414A1 (es)
ZA (1) ZA934970B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
JP4624923B2 (ja) 2003-08-06 2011-02-02 住友化学株式会社 水酸基保護試薬およびそれを用いた水酸基の保護方法
NZ565955A (en) 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
RU2427373C1 (ru) 2010-11-08 2011-08-27 Виктор Вениаминович Тец Средство для индукции эндогенного интерферона
NZ758966A (en) 2017-04-10 2024-08-30 Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Treatment of adipocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
JPS63290867A (ja) * 1987-05-22 1988-11-28 Sds Biotech Kk ウラシル系化合物及び殺菌剤
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
EP0449726B1 (en) * 1990-03-29 1997-06-11 Mitsubishi Chemical Corporation Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives

Also Published As

Publication number Publication date
WO1994001414A1 (en) 1994-01-20
JPH07508983A (ja) 1995-10-05
AU4511693A (en) 1994-01-31
EP0649413A1 (en) 1995-04-26
CA2139836A1 (en) 1994-01-20
ZA934970B (en) 1995-01-09
IL106290A0 (en) 1993-11-15
GB9214720D0 (en) 1992-08-19

Similar Documents

Publication Publication Date Title
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2119912T3 (es) Nuevos aminometilenpeptidos como inmunosupresores.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
BG103805A (en) Trifluoromethylalkylaminotriazolopyrimidines with fungicidal effect
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
UY26186A1 (es) Inhibidores de metaloproteasas
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
DK393187D0 (da) Laegemiddel med antitumorvirkning
ES2134226T3 (es) Derivados de s-triazina como fotoestabilizadores.
IL114294A0 (en) Sterol derivatives
DE69811062D1 (de) Polyaromatische antivirale zusammensetzungen
FI955643A (fi) N-alkyylitiopolyaminnijohdannaiset säteilyltä suojaavina aineina
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BG43856A3 (en) Method for protection from photozoas
MX9304152A (es) Inhibidores de enzimas.
ES2084101T3 (es) Fenoxialcanol como un estabilizante para isotiazolonas.
ES2167952T3 (es) Zuncho de conformacion.
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)